Progyny Reports Mixed Q1 2026 Results Amid Strong Demand for Fertility Benefits

Event summary

  • Progyny reported Q1 2026 revenue of $328.5M, up 1.4% YoY, but gross margin improved to 25.3% from 23.4%.
  • Net income rose to $24.2M from $15.1M YoY, driven by higher operating profit and lower stock-based compensation.
  • The company completed its $200M share repurchase program, buying back 8.8M shares since November 2025.
  • Progyny added 63 new fertility and family building clients, bringing the total to 595 as of March 31, 2026.
  • Guidance for full-year 2026 revenue is $1.365B–$1.405B, with net income projected at $103.7M–$112.3M.

The big picture

Progyny's Q1 2026 results reflect robust demand for fertility benefits, particularly among older women, a trend supported by CDC data. The company's strategic focus on cost containment and member engagement positions it well in a competitive healthcare benefits landscape. However, the loss of a large client and ongoing investments in platform enhancements present challenges to maintaining profitability.

What we're watching

Demand Dynamics
How sustained demand for fertility benefits among women over 30 will impact Progyny's growth trajectory.
Client Retention
Whether Progyny can offset the loss of its large client and maintain momentum in new client acquisitions.
Operational Efficiency
The pace at which Progyny can convert topline growth into sustained profitability amid planned platform investments.